S&P 500   3,638.35 (+0.24%)
DOW   29,910.37 (+0.13%)
QQQ   299.01 (+0.92%)
AAPL   116.59 (+0.48%)
MSFT   215.23 (+0.64%)
FB   277.81 (+0.81%)
GOOGL   1,787.02 (+1.30%)
AMZN   3,195.34 (+0.32%)
TSLA   585.76 (+2.05%)
NVDA   530.45 (+0.20%)
BABA   276.48 (-0.45%)
CGC   29.00 (+7.93%)
GE   10.40 (-0.95%)
MU   64.23 (+1.26%)
AMD   87.19 (+0.55%)
T   29.03 (+0.14%)
NIO   54.00 (+0.58%)
F   9.09 (+0.11%)
ACB   10.47 (+20.21%)
NFLX   491.36 (+1.31%)
GILD   60.03 (+0.89%)
BA   216.50 (-0.51%)
DIS   147.13 (-1.31%)
S&P 500   3,638.35 (+0.24%)
DOW   29,910.37 (+0.13%)
QQQ   299.01 (+0.92%)
AAPL   116.59 (+0.48%)
MSFT   215.23 (+0.64%)
FB   277.81 (+0.81%)
GOOGL   1,787.02 (+1.30%)
AMZN   3,195.34 (+0.32%)
TSLA   585.76 (+2.05%)
NVDA   530.45 (+0.20%)
BABA   276.48 (-0.45%)
CGC   29.00 (+7.93%)
GE   10.40 (-0.95%)
MU   64.23 (+1.26%)
AMD   87.19 (+0.55%)
T   29.03 (+0.14%)
NIO   54.00 (+0.58%)
F   9.09 (+0.11%)
ACB   10.47 (+20.21%)
NFLX   491.36 (+1.31%)
GILD   60.03 (+0.89%)
BA   216.50 (-0.51%)
DIS   147.13 (-1.31%)
S&P 500   3,638.35 (+0.24%)
DOW   29,910.37 (+0.13%)
QQQ   299.01 (+0.92%)
AAPL   116.59 (+0.48%)
MSFT   215.23 (+0.64%)
FB   277.81 (+0.81%)
GOOGL   1,787.02 (+1.30%)
AMZN   3,195.34 (+0.32%)
TSLA   585.76 (+2.05%)
NVDA   530.45 (+0.20%)
BABA   276.48 (-0.45%)
CGC   29.00 (+7.93%)
GE   10.40 (-0.95%)
MU   64.23 (+1.26%)
AMD   87.19 (+0.55%)
T   29.03 (+0.14%)
NIO   54.00 (+0.58%)
F   9.09 (+0.11%)
ACB   10.47 (+20.21%)
NFLX   491.36 (+1.31%)
GILD   60.03 (+0.89%)
BA   216.50 (-0.51%)
DIS   147.13 (-1.31%)
S&P 500   3,638.35 (+0.24%)
DOW   29,910.37 (+0.13%)
QQQ   299.01 (+0.92%)
AAPL   116.59 (+0.48%)
MSFT   215.23 (+0.64%)
FB   277.81 (+0.81%)
GOOGL   1,787.02 (+1.30%)
AMZN   3,195.34 (+0.32%)
TSLA   585.76 (+2.05%)
NVDA   530.45 (+0.20%)
BABA   276.48 (-0.45%)
CGC   29.00 (+7.93%)
GE   10.40 (-0.95%)
MU   64.23 (+1.26%)
AMD   87.19 (+0.55%)
T   29.03 (+0.14%)
NIO   54.00 (+0.58%)
F   9.09 (+0.11%)
ACB   10.47 (+20.21%)
NFLX   491.36 (+1.31%)
GILD   60.03 (+0.89%)
BA   216.50 (-0.51%)
DIS   147.13 (-1.31%)
Log in
ASX:ZLD

Zelira Therapeutics Limited (ZLD.AX) Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range
A$0.05
MA: A$0.05
A$0.05
52-Week Range N/A
Volume311,821 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the development of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and opioid reduction; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer, as well as the potential for cannabinoid formulations to treat diabetes-associated cognitive decline. It has a strategic partnership with CannPal Pty Ltd; and St Vincent's Hospital on opioid reduction study. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited is based in Perth, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.50 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 8 6558 0886
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$981,776.00
Book ValueA$0.04 per share

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable

Receive ZLD News and Ratings via Email

Sign-up to receive the latest news and ratings for ZLD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Zelira Therapeutics Limited (ZLD.AX) (ASX:ZLD) Frequently Asked Questions

What stocks does MarketBeat like better than Zelira Therapeutics Limited (ZLD.AX)?

Wall Street analysts have given Zelira Therapeutics Limited (ZLD.AX) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Zelira Therapeutics Limited (ZLD.AX) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Zelira Therapeutics Limited (ZLD.AX)'s earnings last quarter?

Zelira Therapeutics Limited (ZLD.AX) (ASX:ZLD) posted its quarterly earnings data on Friday, February, 22nd. The company reported $0.00 earnings per share for the quarter.
View Zelira Therapeutics Limited (ZLD.AX)'s earnings history
.

Who are some of Zelira Therapeutics Limited (ZLD.AX)'s key competitors?

What other stocks do shareholders of Zelira Therapeutics Limited (ZLD.AX) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zelira Therapeutics Limited (ZLD.AX) investors own include Saputo Inc. (SAP.TO) (SAP), The Western Union (WU), TransEnterix (TRXC), Intuitive Surgical (ISRG) and Heat Biologics (HTBX).

Who are Zelira Therapeutics Limited (ZLD.AX)'s key executives?

Zelira Therapeutics Limited (ZLD.AX)'s management team includes the following people:
  • Mr. Osagie O. Imasogie, Founder & Chairman (Age 58, Pay $84k)
  • Dr. Richard Miles Hopkins, MD & Director (Age 53, Pay $328.5k)
  • Mr. Harry Karelis B.Sc (Hons), MBA, CFA, F.Fin, FAICD, Co-Founder & Non-Exec. Deputy Chairman (Age 50, Pay $120k)
  • Mr. Jason William Peterson, Co-Founder & Non-Exec. Director
  • Dr. Oludare Odumosu, CEO of USA, MD of USA & Director
  • Mr. Timothy Ryan Slate, Company Sec.
  • Dr. Patty Washer, Clinical Trial Consultant

What is Zelira Therapeutics Limited (ZLD.AX)'s stock symbol?

Zelira Therapeutics Limited (ZLD.AX) trades on the ASX under the ticker symbol "ZLD."

How big of a company is Zelira Therapeutics Limited (ZLD.AX)?

Zelira Therapeutics Limited (ZLD.AX) has a market capitalization of $0.00 and generates $981,776.00 in revenue each year.

What is Zelira Therapeutics Limited (ZLD.AX)'s official website?

The official website for Zelira Therapeutics Limited (ZLD.AX) is www.zeldatherapeutics.com.

How can I contact Zelira Therapeutics Limited (ZLD.AX)?

The company can be reached via phone at 61 8 6558 0886.

This page was last updated on 11/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.